Abstract
Comparative gene identification-58 (CGI-58), also designated as α/β-hydrolase domain containing-5 (ABHD-5), is a lipid droplet-associated protein that activates adipose triglyceride lipase (ATGL) and acylates lysophosphatidic acid. Activation of ATGL initiates the hydrolytic catabolism of cellular triacylglycerol (TG) stores to glycerol and nonesterified fatty acids. Mutations in both ATGL and CGI-58 cause “neutral lipid storage disease” characterized by massive accumulation of TG in various tissues. The analysis of CGI-58-deficient (Cgi-58−/−) mice, presented in this study, reveals a dual function of CGI-58 in lipid metabolism. First, systemic TG accumulation and severe hepatic steatosis in newborn Cgi-58−/− mice establish a limiting role for CGI-58 in ATGL-mediated TG hydrolysis and supply of nonesterified fatty acids as energy substrate. Second, a severe skin permeability barrier defect uncovers an essential ATGL-independent role of CGI-58 in skin lipid metabolism. The neonatal lethal skin barrier defect is linked to an impaired hydrolysis of epidermal TG. As a consequence, sequestration of fatty acids in TG prevents the synthesis of acylceramides, which are essential lipid precursors for the formation of a functional skin permeability barrier. This mechanism may also underlie the pathogenesis of ichthyosis in neutral lipid storage disease patients lacking functional CGI-58.
Keywords: Gene Knockout, Lipase, Lipolysis, Liver, Skin, ATGL, CGI-58/ABHD5, Neutral Lipid Storage Disease, Skin Barrier, Triacylglycerol Metabolism
Introduction
Fatty acids (FA)3 are major energy substrates and essential components of membrane lipids as well as of numerous bioactive lipid species. Because excessive cellular concentrations of nonesterified FA are toxic, eukaryotic cells detoxify them by esterification to triacylglycerols (TG), which are subsequently stored in cellular lipid droplets (LD). Adipose tissue is the major storage organ for TG. However, some LD are found in essentially all cell types and tissues. Depending on the nutritional status and the energy demand of an organism, TG are synthesized (lipogenesis) or catabolized (lipolysis). Defects in the control of the finely regulated balance between lipogenesis and lipolysis result in the development of metabolic disorders such as obesity, type II diabetes, lipodystrophy, and neutral lipid storage disease (NLSD) (1–6).
Hydrolysis of TG is mediated by the enzymatic activity of adipose triglyceride lipase (ATGL) (7–9) and hormone-sensitive lipase (10, 11). Whereas hormone-sensitive lipase-deficient mice exhibit a relatively benign phenotype (12, 13), mice lacking ATGL massively accumulate TG in multiple tissues, exhibit a severe defect in energy metabolism, and die prematurely due to cardiac dysfunction (14). Similarly, humans with mutations in the ATGL gene lacking normal enzyme function develop NLSD associated with skeletal and cardiac myopathy (15). In severe cases, cardiomyopathy necessitates heart transplantation (16).
Studies in this laboratory and by others demonstrated that both human and murine ATGL are stimulated by a protein designated as CGI-58 (comparative gene identification-58) (17, 18) or ABHD5 (α/β-hydrolase domain containing-5) (19). Although the exact mechanism of the activation process is not understood, CGI-58 is known to be part of the lipolytic complex (20, 21). The protein binds to LD via interaction with proteins of the PAT family (e.g. perilipin, adipophilin, or muscle LD protein) (22). Hormonal stimulation leads to dissociation of CGI-58 from these binding partners and its translocation to the proximity of ATGL (23, 24). In addition to ATGL activation, CGI-58 was shown in in vitro experiments to acylate lysophosphatidic acid generating phosphatidic acid (25, 26). The physiological role of this reaction in vivo is currently unknown.
The importance of CGI-58 for TG catabolism in humans is evident from clinical observations in patients affected with mutations in the gene encoding CGI-58. Mutant versions of CGI-58 fail to stimulate ATGL (17), and similarly to patients with ATGL mutations, individuals with defective CGI-58 accumulate TG in multiple tissues (15). However, the symptoms exhibited by the two groups of patients differ in two important ways. In contrast to patients with dysfunctional ATGL, CGI-58 mutations in humans are always associated with lamellar ichthyosis, a rare skin disorder, whereas myopathy, a hallmark of patients with NLSD associated with skeletal and cardiac myopathy, is less commonly observed. Accordingly, the disorder caused by defective CGI-58 was designated “neutral lipid storage disease with ichthyosis (NLSDI)” (15), originally known as Chanarin-Dorfman syndrome (1, 2).
To address the potential rate-limiting role of CGI-58 in the regulation of cellular TG catabolism and to uncover currently unknown molecular mechanisms leading to disease development, we generated a CGI-58-deficient mouse model by disruption of exon 4–7 (coding for amino acids 172–351 of the mature protein), a gene region that has been linked to NLSDI development in humans (17, 27). The observed phenotype of CGI-58-deficient mice included the following: (i) growth retardation, (ii) systemic TG accumulation in multiple tissues, and (iii) an impaired development of the skin permeability barrier.
EXPERIMENTAL PROCEDURES
Generation of CGI-58-deficient Animals
A 3.5-kb CGI-58 intron 3 sequence was amplified by PCR using HM-1 genomic embryonic stem (ES) cell DNA as template and cloned into pBlueKS(−) (Stratagene, La Jolla, CA) to generate the 5′ part of the long arm of the targeting vector. The 3′ part of the long arm of the targeting vector, a 6.0-kb genomic sequence encompassing CGI-58 exon 4–7, was amplified by PCR and cloned into pBlueKS(−). The 5′ and 3′ parts of the targeting vector were cloned upstream and downstream of a single loxP sequence flanked by compatible restriction sites. To generate the short arm, a 2.0-kb CGI-58 DNA fragment downstream to exon 7 was amplified and cloned into pBK-CMV harboring a loxP-flanked neomycin resistance cassette. Subsequently, the 3.2-kb DNA fragment encompassing the selection cassette and the short arm was cloned into the plasmid containing the long arm of the targeting vector. A diphtheria toxin A cassette was introduced 5′ to the long arm to generate the final targeting vector. The linearized targeting vector was transfected into HM-1 ES cells by electroporation. G418-resistant clones were picked and expanded. Clones that underwent homologous recombination were transfected with a plasmid encoding Cre-recombinase (28) to generate ES cell clones harboring a null CGI-58 allele. Four independent clones were injected into 3.5-day-old C57Bl/6 blastocysts and transferred into pseudo-pregnant recipient mice. Chimeric animals with a high degree of coat color chimerism were bred with C57Bl/6 mice. Germ line transmission of the CGI-58 manipulated allele was observed by coat color and verified by Southern and Northern blotting. Genotyping of mice was routinely performed by PCR analysis of tail tip DNA using FIREPol® DNA polymerase (Solis BioDyne, Tartu, Estonia) and three primers in a single reaction as follows: forward, 5′-GTC ATG GTT GTG GGG AAA TC-3′; reverse I, 5′-AGG AAG GGG TAT TCT GCA GG-3′; and reverse II, 5′-CTT CTT CCA GCT GCT TCT GC-3′. Atgl−/− mice (ATGL knock-out mice) were generated as described previously (14). Animals were housed in a pathogen-free barrier facility (12-h light/dark cycle) and fed a standard laboratory chow.
Southern and Northern Blot Analysis
Genomic DNA was prepared with the DNeasy® blood and tissue kit (Qiagen Inc., Hilden, Germany) according to the manufacturer's protocol. For restriction fragment analysis, 10 μg of genomic DNA were digested with EcoRI restriction enzymes. DNA fragments were separated by agarose gel electrophoresis followed by depurination with 0.2 n HCl and denaturation with 0.5 n NaOH. After neutralization with Tris-HCl, pH 7.5, DNA was transferred onto a Hybond-N+ membrane (GE Healthcare) and hybridized with a 32P-labeled probe. The external probe for DNA analysis was generated by PCR from HM-1 genomic ES cell DNA using the following primer pair: forward, 5′-GGA ATT CCC AGA CGC CAG TGA CTA AGG-3′, and reverse, 5′-GGA ATT CAA CTC CTG CCT ATC TCT GTG G-3′. The PCR primers introduced the EcoRI restriction enzyme sites (underlined). The PCR product was ligated into the respective restriction enzyme site of pBlueKS(−) plasmid. For Northern blot analysis, total RNA was isolated from mouse tissue using the TRI Reagent® procedure according to the manufacturer's protocol (Invitrogen). Ten μg of total RNA were resolved by formaldehyde/agarose gel electrophoresis and blotted onto a Hybond-N+ membrane. Murine CGI-58 mRNA was hybridized with a 32P-labeled murine CGI-58 cDNA probe generated by PCR from epididymal adipose tissue as described previously (17). Gene-specific probes for both Southern and Northern blot analysis were labeled with [α-32P]dCTP (GE Healthcare) using the Prime-a-Gene® DNA labeling kit according to manufacturer's protocol (Promega, Madison, WI). After hybridization and washing, signals were visualized by exposure to PhosphorImager Screen (GE Healthcare).
Western Blot Analysis
15 μg of LD protein were separated by 10% SDS-PAGE according to standard protocols (29), blotted onto polyvinylidene fluoride membrane (Carl Roth GmbH, Karlsruhe, Germany), and hybridized with a rabbit polyclonal antiserum raised against murine CGI-58 (1:5,000 dilution; kindly provided by Dr. Dawn L. Brasaemle). Specifically bound immunoglobulins were detected in a second reaction using horseradish peroxidase-conjugated anti-rabbit IgG antibody (1:10,000 dilution) and visualized by enhanced chemiluminescence detection (ECL, GE Healthcare).
Murine Embryonic Fibroblast (MEF) Isolation and Experiments
MEF were derived from E12.5-day-old Cgi-58−/− (CGI-58 knock-out mice), Atgl−/−, and wild-type mouse embryos and cultured on gelatinized plates in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum, 100 IU/ml penicillin (Invitrogen), and 100 μg/ml streptomycin. To investigate TG synthesis in MEF, confluent cell layers of MEF (passage 4) were incubated in the presence of oleic acid (200 and 400 μm, respectively) bound to defatted BSA at a molar FA/BSA ratio of 3:1. After 24 h, the medium was removed; cells were washed twice with PBS, and the cellular TG content was measured as outlined below. For in vivo radiolabeling of MEF TG stores, confluent cell layers were incubated for 24 h with 400 μm oleate (containing 2.5 μCi of [9,10-3H]oleic acid/μmol of oleate) bound to BSA at a molar FA/BSA ratio of 3:1. LD were isolated and purified by density gradient centrifugation as described previously (17). For determining LD TG and protein concentrations, aliquots of LD preparations were adjusted to a final concentration of 0.1% (v/v) Triton X-100. TG and protein concentrations were measured using commercial kits (Thermotrace triglycerides reagent, Thermo Electron Corp., Victoria, Australia, and Bradford protein assay, Bio-Rad) and were found to be comparable in all preparations (typically 80 μg of protein/μmol of TG). The LD TG hydrolase activities were determined by self-digestion of purified LD as described previously (17).
Assay for Skin and Liver TG Hydrolase Activity
Full thickness skin and liver were surgically prepared; subcutaneous tissue was scraped off, and skin and liver tissue were washed in ice-cold PBS supplemented with 100 units/ml heparin and 1 mm EDTA. Epidermis was separated from dermis by incubating skin tissue in PBS containing 10 mm EDTA and 1 g/liter glucose at 37 °C for 45 min. Homogenization of tissues was performed on ice in buffer A (0.25 m sucrose, 1 mm EDTA, 1 mm dithiothreitol, 20 μg/ml leupeptin, 2 μg/ml antipain, 1 μg/ml pepstatin, pH 7.0) using an Ultra Turax (IKAR, Janke & Kunkel, Germany). After centrifugation at 20,000 × g and 4 °C for 30 min, the infranatant was subjected to ultracentrifugation at 100,000 × g and 4 °C for 90 min. The TG-free infranatant was assayed using a phospholipid-emulsified triolein (330 μm) substrate containing [9,10-3H]triolein (PerkinElmer Life Sciences) with or without addition of 200 ng of GST-tagged CGI-58 (GST-CGI-58) as described previously (17).
Lipid Analysis
Total lipids were extracted twice from murine total carcass or tissue homogenates with chloroform/methanol/glacial acetic acid (66:33:1, v/v), and phase separation was achieved by the addition of water. Total lipids from MEF were extracted three times in hexane/isopropyl alcohol (3:2, v/v). After lipid extraction, tissue homogenates or MEF were solubilized in 0.3 n NaOH, 0.1% (w/v) SDS at 65 °C for several hours, and the protein content was determined using BCA reagent (Pierce) and BSA as standard. For the extraction of covalently bound lipids, the alkaline-hydrolyzed samples were extracted with chloroform/methanol/glacial acetic acid (66:33:1, v/v). After centrifugation (1,400 × g, 15 min), the lower organic phase was collected, and lipids were analyzed as described below.
Lipids were dried, reconstituted in chloroform, and spotted onto a Silica Gel 60 plate (Merck). Neutral lipids were resolved in hexane/diethyl ether/glacial acetic acid (70:29:1, v/v) with authentic standards. Epidermal ceramide species were separated twice using chloroform/methanol/glacial acetic acid (190:9:1 v/v/v) as solvent system (30). Spots were visualized by established carbonization method or with iodine vapor, and radioactivity was measured by liquid scintillation counting. Dried lipids of murine tissues or MEF were redissolved in 1% (v/v) Triton X-100, and TG content was measured using Infinity triglycerides reagent (Thermo Electron Corp., Victoria, Australia).
ω-Hydroxyceramides (ω-OH-ceramides), acylceramides, and phospholipids were analyzed by tandem mass spectrometry (MSMS) using a Quantum TSQ (Thermo), coupled to an Accela ultra performance liquid chromatography (UPLC) system (Thermo). The column was a Thermo Hypersil GOLD, 100 × 1 mm (1.9 μm), and operated at 50 °C. Water (solvent A) and acetonitrile/isopropyl alcohol (5:2, v/v, solvent B), both containing 1% of NH4Ac (1 m aqueous solution) and 0.1% formic acid, were used as solvent system. The gradient started with 35% solvent B, increased to 70% within 4 min, then to 100% within 16.5 min, and remained at 100% for 9.5 min. After the analysis, the column was equilibrated at starting conditions for 5 min. The flow rate was 0.250 ml/min. Ionization was performed by a heated electrospray ionization operating in the positive ion mode with a spray voltage of 4,000 V. Ceramide species were identified by a precursor ion scan for the characteristic fragment at m/z 264.3. Argon was used as collision gas. The collision energy was set to 30 V for analyses of ω-OH-ceramides and to 50 V for acylceramides. Collision gas pressure was 0.7 millitorr. Samples were diluted with solvent B, and N-(dodecanoyl) sphing-4-enine (Avanti Polar Lipids Inc., Alabaster, AL) was added as an internal standard. Phosphatidylcholine species were measured by a precursor ion scan for the characteristic fragment at m/z 184.1 and 30 V collision energy. Phosphatidylethanolamine species were measured by a neutral loss scan for m/z 141.0 and 25 V collision energy. Phosphatidylcholine and phosphatidylethanolamine 24:0 (12:0/12:0, Avanti Polar Lipids Inc.) were added as internal standard, respectively.
Labeling of Epidermal Lipids
Radiolabeling of lipid species in the epidermis was performed as described for cultured skin fibroblasts (31). In brief, dorsal 3 × 3-mm sized epidermal sheets were incubated in DMEM containing 1% (w/v) delipidated BSA and 400 μm oleate (12.5 μCi/μmol oleate) bound to delipidated BSA at a molar FA/BSA ratio of 3:1. After 5 h, epidermal sheets were washed with PBS and chased in the presence or absence of 20 μm orlistat in DMEM containing 1% (w/v) delipidated BSA. At various time points, epidermal sheets were washed, and lipids were extracted with chloroform/methanol/glacial acetic acid (66:33:1, v/v), separated by TLC, and measured as described above.
Blood Chemistry
Anesthetized newborn mice were sacrificed by decapitation. Blood samples were collected using a Microvette® CB 300 (Sarstedt, Nümbrecht, Germany). Plasma FA and TG concentrations were determined using commercial kits (Wako Chemicals, Neuss, Germany; Thermo Electron Corp., Victoria, Australia). Blood glucose levels were measured using blood glucose strips and the Accu-Check glucometer (Roche Diagnostics).
Histology, Immunohistochemistry, and Electron Microscopy
Skin pieces were fixed overnight in 4% neutral buffered formalin and embedded in paraffin, cut into 4–6-μm-thick sections, and stained with hematoxylin and eosin using established protocols. For visualization of vacuoles within granulocytes, blood smears from newborn mice were stained by combined May-Grünwald-Giemsa according to established protocols. To visualize neutral lipids in liver tissue, tissue samples were snap-frozen in liquid nitrogen, sectioned, and stained with Sudan III following a standard protocol. For determination of keratinocyte differentiation and proliferation, antibodies against cytokeratin 14 (CK14, Novocastra Laboratories, Newcastle upon Tyne, UK), cytokeratin 6 (CK6, Covance Inc., Emeryville, CA), fillagrin (Fila, Covance), and Ki67 (Novocastra) were evaluated for use on formaldehyde-fixed paraffin-embedded tissue specimens using different methods of pretreatment. Tissue sections were deparaffinized by xylene, rehydrated in graded alcohols, and submitted to microwave epitope retrieval (40 min at 150 watts in 0.01 m sodium citrate buffer, pH 6.0). After treatment in 1% H2O2 for 10 min, sections were incubated for 1 h using Dako antibody-diluent (Dako, Vienna, Austria). Final dilutions were as follows: cytokeratin 14 (1:50), cytokeratin 6 (1:500), fillagrin (1:500), and Ki67 (1:500). After enhancement using MultiLink Dako (E0453) diluted 1:100 and StreptABComplex/horseradish peroxidase Dako (K0377) diluted 1:100 for 30 min each, detection was performed using AEC Substrate Chromogen Ready-to-Use (Dako K3464) under microscopic control. For electron microscopy, tissue was fixed in 2.5% glutaraldehyde in 0.01 m cacodylate buffer, pH 7.3, dehydrated, and embedded in resin (AGAR-100, Agar Scientific, Essex, UK). 50-nm-thick sections were contrasted with uranyl acetate/lead citrate and studied in a Philips CM 100 electron microscope.
Skin Permeation Assay and Skin Grafts
Newborn mice were euthanized, immersed in PBS containing 0.1% toluidine blue (Sigma) for 4 h, and photographed (32). Full-thickness skin pieces (∼1 cm2) from newborn wild-type and Cgi-58−/− mice were grafted onto the left and right sides of athymic nude mice (Charles River Laboratories, Sulzfeld, Germany). Wound edges were sutured. After 3 weeks, the grafted skin was investigated for hair growth, and sections were stained for differentiation markers as described above.
Statistical Analysis
Statistical significance was determined by the Student's unpaired t test (two-tailed). Group differences considered significant for p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***).
RESULTS
Generation of CGI-58-deficient Mice
To investigate the physiological role of CGI-58 in vivo, we generated mice lacking functional CGI-58. For that purpose, we designed a targeting vector harboring a loxP-flanked neomycin resistance gene cassette (neo) downstream to the polyadenylation sequence and an additional loxP recombination site in intron 3 of the murine cgi-58 gene (Fig. 1A). This vector was electroporated into ES cells. Cells that underwent homologous recombination were selected and subsequently transfected with a plasmid encoding Cre-recombinase. ES cell clones harboring a CGI-58 null allele were used for blastocyst injection to generate CGI-58-deficient mice. Southern blot analysis of mouse genomic DNA confirmed the disruption of the Cgi-58 gene (Fig. 1B). Cgi-58−/− mice showed no expression of CGI-58 mRNA analyzed by Northern blotting (Fig. 1C). Mice heterozygous for the targeted allele exhibited ∼50% reduced CGI-58 mRNA expression levels compared with wild-type mice. CGI-58 protein levels in Cgi-58−/− mice were analyzed by Western blot analysis of LD proteins isolated from newborn mice (Fig. 1D). Using a polyclonal rabbit anti-CGI-58 antiserum, wild-type and heterozygous Cgi-58+/− mice exhibited a signal specific for CGI-58 protein at the expected molecular mass of 39 kDa, which was not detectable in Cgi-58−/− mice.
Growth Retardation, Postnatal Death, and NLSD with Ichthyosis in Mice Lacking CGI-58
Cgi-58−/− mice died within 16 h after birth, were smaller, and weighed less than wild-type littermates (Fig. 2A and Table 1). Genotype analysis of 1042 newborn animals from 143 heterozygous intercrosses demonstrated normal Mendelian distribution of the mutant CGI-58 allele (wild-type 253, 24.3%; heterozygous 535, 51.3%; Cgi-58−/− 254, 24.4%; p < 0.001 by χ2 test). The lack of CGI-58 was associated with ectopic lipid accumulation as evident from increased TG content in carcasses (1.8-fold, Fig. 2B) and granulocyte vacuolization (Jordans' anomaly) (Fig. 2C) (33). Histological analysis of Cgi-58−/− epidermis exhibited hyperkeratosis characterized by tightly condensed lamellar sheets in the stratum corneum and increased numbers of cell layers in the stratum spinosum (Fig. 2D). These alterations are characteristics for lamellar ichthyosis and indicate that mice with defective CGI-58 develop a condition similar to human NLSDI.
TABLE 1.
Wild type | Cgi-58+/− | Cgi-58−/− | |
---|---|---|---|
Length (mm) | 30.4 ± 0.63 | 30.2 ± 0.75 | 25.6 ± 0.65a |
Weight (g) | 1.36 ± 0.090 | 1.36 ± 0.102 | 1.09 ± 0.088a |
a Statistical significance was determined by the two-tailed Student's t-test, p < 0.001.
Circulating energy substrates were markedly decreased in Cgi-58−/− mice (Table 2). Although plasma concentrations of FA, TG, and glucose in heterozygous Cgi-58+/− mice were comparable with those in wild-type mice, they were decreased by 60, 48, and 74% in Cgi-58−/− mice, respectively. Considering that the marked hypoglycemia may cause the early death of Cgi-58−/− mice, glucose was injected to transiently raise plasma glucose levels. However, this treatment did not rescue Cgi-58−/− mice from premature death. Similarly, increasing humidity and application of Vaseline® to the skin of newborns to prevent desiccation of the animals failed to significantly prolong the life span of Cgi-58−/− mice.
TABLE 2.
Wild type | Cgi-58+/− | Cgi-58−/− | |
---|---|---|---|
FA (mmol/liter) | 0.50 ± 0.076 | 0.46 ± 0.104 | 0.20 ± 0.038a |
TG (mg/deciliter) | 69.7 ± 11.31 | 60.0 ± 14.18 | 36.2 ± 8.87b |
Glucose (mg/deciliter) | 67 ± 8.2 | 61 ± 6.6 | 16 ± 5.6a |
a Statistical significance was determined by the two-tailed Student's t test, p < 0.01.
b Statistical significance was determined by the two-tailed Student's t test, p < 0.001.
CGI-58 Is Rate-limiting in MEF TG Catabolism via Activation of ATGL Enzyme Activity
To define the impact of CGI-58 deficiency on cellular TG metabolism, we isolated MEF from E12.5-day-old Cgi-58−/−, Atgl−/−, and wild-type embryos and incubated these cells with increasing concentrations of oleic acid to induce lipogenesis. TG accumulation was increased in both Cgi-58−/− and Atgl−/− MEF (1.6- and 1.9-fold, respectively, at 400 μm oleic acid) compared with wild-type MEF (Fig. 3A). Concomitantly, the LD-associated TG hydrolase activities of Cgi-58−/− and Atgl−/− MEF were decreased by 76 and 81%, respectively, compared with wild-type MEF (Fig. 3B). Defective lipolysis was partially rescued by addition of purified, recombinant GST-CGI-58 to LD of Cgi-58−/− MEF (Fig. 3B) but not of Atgl−/− MEF. Taken together, these findings suggest that excessive lipid storage in Cgi-58−/− MEF is caused by defective activation of ATGL-mediated TG hydrolysis.
Hepatic Steatosis in Cgi-58−/− Mice Is Associated with Impaired TG Catabolism
To address the role of CGI-58 in liver TG catabolism, we measured TG concentrations and TG hydrolase activities in liver lysates from newborn Cgi-58−/−, Atgl−/−, and wild-type mice. Liver TG contents (Fig. 4A) were markedly increased in Cgi-58−/− (4.1-fold) and Atgl−/− mice (4.6-fold) compared with wild-type newborns. Sudan III staining of histological liver sections from Cgi-58−/− and Atgl−/− newborns confirmed an increase of neutral lipid content (Fig. 4B). In parallel, liver TG hydrolase activities (Fig. 3C) were significantly decreased in Cgi-58−/− (−73%) and Atgl−/− mice (−46%). The addition of recombinant GST-CGI-58 (Fig. 4C) substantially stimulated TG hydrolysis (8.6-fold) in CGI-58-deficient liver lysates and exceeded wild-type TG hydrolase activities (1.7-fold). In contrast, addition of recombinant GST-CGI-58 to ATGL-deficient liver lysates caused a marginal increase in TG hydrolase activities (1.2-fold).
Defective Skin Permeability Barrier and Keratinocyte Differentiation of CGI-58-deficient Skin
To assess whether the distinct morphological alterations particularly in the stratum corneum of the Cgi-58−/− epidermis (Fig. 2D) are associated with a loss of the skin permeability barrier function, we investigated the penetration of an aqueous toluidine blue solution into the epidermis of newborn mice. Cgi-58−/− mice showed massive staining when exposed to toluidine blue for 4 h indicating a leaky skin barrier (Fig. 5A). Wild-type or Atgl−/− pups were completely resistant to toluidine blue permeation consistent with an intact skin barrier function.
Immunohistochemical analysis of the epidermis revealed delayed keratinocyte differentiation in Cgi-58−/− compared with wild-type mice (Fig. 5B). In the healthy skin, cytokeratin 14, a marker of proliferating basal keratinocytes, was almost exclusively present in basal cells of the squamous epithelium. In Cgi-58−/− skin sections, cytokeratin 14 staining was much more diffuse reaching into upper layers of the stratum spinosum. Cytokeratin 6 is usually expressed in the outer root sheath of hair follicles and nail beds and not detected in the interfollicular epidermis. Increased cytokeratin 6 expression is typically observed in hyper-proliferating epithelia or aberrant epidermal differentiation as seen in ichthyosis and psoriasis (34). Consistent with this defect, pronounced cytokeratin 6 protein was observed in the epidermis of Cgi-58−/− but not in wild-type skin. Fillagrin, a marker for terminally differentiated keratinocytes, was barely detectable in Cgi-58−/− sections but clearly visible in wild-type skin samples. Notably, the localization of the cell proliferation marker Ki67 (35) was not changed in Cgi-58−/− compared with wild-type epidermis (Fig. 5B, lowest panel). Taken together, the immunohistochemical analysis revealed that CGI-58 deficiency results in delayed keratinocyte differentiation and corneocyte formation, which may contribute to the dysfunctional stratum corneum.
To investigate whether the skin defect is specifically caused by the lack of CGI-58 in the skin and not by a defect of the metabolite supply from the circulation, we transplanted Cgi-58−/− skin grafts onto nude mice. As shown in Fig. 6A, Cgi-58−/− transplants exhibited severe growth retardation and lacked fur development on the recipient organism. In comparison, control grafts derived from wild-type newborns developed normally on nude mice. Thus, the lack of CGI-58 in the transplanted skin cannot be compensated by physiological CGI-58 expression and function in tissues of the recipient organism. As shown in the skin sections of newborn Cgi-58−/− mice, cytokeratin 14 staining, typically observed in the basal layer of the epidermis, and cytokeratin 6 staining were present in an extended area of Cgi-58−/− skin grafts (Fig. 6B). Apparently, defective skin development due to the absence of CGI-58 reflects a direct requirement for the protein in the skin and is not caused by systemic CGI-58 deficiency.
Impaired Skin TG Catabolism Affects Generation of Essential Epidermal Lipids in the Cgi-58−/− Epidermis
Epidermal differentiation is known to involve remodeling of lipid stores and synthesis of certain lipid classes such as acylceramides, wax esters, and phospholipids. Because CGI-58 plays a central role in TG catabolism of several tissues and cell types, we hypothesized that inadequate generation of TG metabolites in CGI-58-deficient skin could impact keratinocyte differentiation and permeability barrier function. Therefore, we determined the TG content in the skin of newborn Cgi-58−/−, Atgl−/−, and wild-type mice. Both dermal and epidermal TG contents were significantly increased in Cgi-58−/− (1.5- and 2.0-fold, respectively) and Atgl−/− (1.6- and 1.3-fold, respectively) compared with wild-type skin (Fig. 7A). Consistent with the elevated dermal TG levels, TG hydrolase activities were markedly decreased in dermal lysates of both Cgi-58−/− (−51%) and Atgl−/− (−52%) mice compared with those of wild-type mice (Fig. 7B). Notably, although epidermal TG hydrolase activities were drastically decreased in lysates of Cgi-58−/− animals (−81%), they were completely unaffected in lysates of Atgl−/− mice. Addition of recombinant GST-CGI-58 significantly improved both epidermal and dermal TG hydrolase activities in lysates of Cgi-58−/− mice but did not affect TG hydrolysis of Atgl−/− samples (data not shown). These findings are in line with the concept that in wild-type epidermis a “non-ATGL” TG hydrolase is active in a manner that depends on CGI-58 stimulation.
Acylceramides are obligatory precursors for the covalent binding of ω-OH-ceramides to corneocyte proteins (predominantly involucrin) and the formation of a water-resistant structure in the stratum corneum, also designated as cornified lipid envelope (CLE) (36). To investigate whether the skin barrier defect in Cgi-58−/− mice is linked to changes in epidermal ceramide metabolism, we measured the concentrations of ω-OH-ceramides covalently bound to the CLE, free extractable, unbound ω-OH-ceramides, and acylceramides in the epidermis of newborn Cgi-58−/−, Atgl−/−, and wild-type mice by UPLC-MSMS. All species of covalently bound ω-OH-ceramides were drastically decreased (supplemental Fig. S1A) in Cgi-58−/− epidermis. The total of covalently bound ω-OH-ceramides (as calculated from the sum of individual covalently bound ω-OH-ceramide species) was decreased by 85 and 84% in Cgi-58−/− epidermis compared with wild-type and Atgl−/− epidermis, respectively (Fig. 8A). In contrast, free ω-OH-ceramide species, which were barely detectable in wild-type and Atgl−/− mice, were substantially increased in Cgi-58−/− samples (supplemental Fig. S1B). The total of free ω-OH-ceramide species was 13.5-fold higher in Cgi-58−/− epidermis compared with wild-type samples and 9.3-fold higher compared with Atgl−/− samples (Fig. 8A). Strikingly, acylceramides were undetectable in the Cgi-58−/− epidermis (Fig. 8A and supplemental Fig. S1C).
Acylceramides are generated by esterification of free ω-OH-ceramides with primarily oleic or linoleic acid (36). Whether oleic or linoleic acid originates from the cellular nonesterified FA or the LD TG pool is currently unknown. We hypothesized that the impaired TG hydrolase activity and consequently the decreased release of oleic acid from the TG pool in Cgi-58−/− epidermis may prevent acylceramide formation. To test this hypothesis, we analyzed the incorporation of exogenously added oleic acid into acylceramides of epidermal sheets derived from newborn Cgi-58−/− and wild-type mice in vitro. After 5 h of pulse labeling with 400 μm oleate (including [9,10-3H]oleate as tracer), epidermal sheets were chased for a period of 6 h, and radioactivity in the TG, phospholipid (phosphatidylcholine and phosphatidylethanolamine), and acylceramide fractions was measured (Fig. 8, B–D). Under these conditions, the radioactivity in the TG pool of wild-type epidermal cultures declined (Fig. 8B), whereas it increased in both the phospholipid (Fig. 8C) and acylceramide fractions (Fig. 8D) over time. In contrast, in Cgi-58−/− epidermis the radioactivity remained in the TG pool, consistent with the concept that oleic acid is not released from TG and becomes trapped within LD. Accordingly, the transfer of labeled oleic acid to phospholipids and more importantly to acylceramides was attenuated in Cgi-58−/− epidermis (Fig. 8, C and D). To analyze whether the sequestration of FA in TG affects the epidermal phospholipid species, we determined amounts and FA composition of major phospholipids (phosphatidylcholine and phosphatidylethanolamine) by UPLC-MSMS in extracts of Cgi-58−/−, Atgl−/−, and wild-type mice (supplemental Fig. S2, A and B). In contrast to ω-OH-ceramides and acylceramides, phosphatidylcholine and phosphatidylethanolamine species were unchanged in the epidermis of Cgi-58−/− as compared with wild-type and Atgl−/− mice.
To confirm the crucial role of epidermal TG catabolism for acylceramide synthesis, we measured the transfer of oleic acid from TG to acylceramides of wild-type tissue cultures in the absence or presence of orlistat, a potent lipase inhibitor impairing TG hydrolysis (Fig. 8, E–G) (37). Similarly as observed in Cgi-58−/− epidermis, the TG catabolism was impaired in the presence of orlistat, and no transfer of radioactivity from TG to phospholipids and acylceramides was observed (Fig. 8, F and G). In contrast, in the absence of orlistat the radioactivity in the TG fraction decreased, whereas the incorporation of radioactivity into phospholipids and acylceramides increased (Fig. 8, F and G). As orlistat shows little or no effect on phospholipase activities (37), these findings further demonstrate the essential role of epidermal TG catabolism for acylceramide synthesis and the development of an intact skin permeability barrier.
DISCUSSION
To elucidate the physiological function of CGI-58 in lipid homeostasis and skin development, we generated and characterized a CGI-58 knock-out mouse model. We show that Cgi-58−/− mice exhibit growth retardation, systemic TG accumulation in multiple tissues, and hepatic steatosis. They display severely reduced plasma TG, FA, and glucose levels. Notably, the animals suffer from impaired development of the skin permeability barrier resulting in rapid dehydration. Because newborn mice virtually exhibit no white adipose tissue, they are dependent on suckling maternal milk. However, Cgi-58−/− mice did not suckle. The severe skin phenotype combined with profound alterations in energy supply leads to the early death of Cgi-58−/− animals within 1 day after birth.
CGI-58 was previously shown to markedly increase TG hydrolase activity of ATGL (17). Consistent with these in vitro observations, Cgi-58−/− mice exhibited increased TG contents in the whole carcass, the liver, and cultured MEF. The magnitude of lipid accumulation in newborn CGI-58-deficient animals or cultivated cells was similar to that observed in ATGL-deficient mice. Comparative analysis of TG storage and LD-associated TG hydrolase activities in Cgi-58−/− and Atgl−/− MEF revealed that a defect in ATGL activation accounts for excessive neutral lipid storage. Accordingly, CGI-58 exhibits a crucial role in cellular TG homeostasis and energy catabolism via its impact on regulating ATGL activity. Unfortunately, the lethal phenotype within hours after birth prevented an extensive characterization of the metabolic consequences of systemic lipid accumulation, such as energy substrate utilization or insulin response. Elucidation of the tissue-specific effects of CGI-58 in these processes will thus require the characterization of conditional CGI-58 knock-out mice.
Newborn Cgi-58−/− mice exhibited an increased hepatic TG content compared with wild-type mice suggesting a role of CGI-58 in the regulation of the hepatic fat content. Hepatosteatosis was associated with markedly lower TG hydrolase activities in liver lysates of CGI-58-deficient mice than those of wild-type animals. Hepatic TG levels and lipolytic activities were similar to those in newborn Atgl−/− mice. In contrast to Atgl−/− liver samples, however, the TG hydrolase activities of Cgi-58−/− liver samples could be completely restored by the addition of recombinant GST-CGI-58. These findings indicate that the lipolytic defect originates predominantly from reduced ATGL activity in the liver rather than the action of a non-ATGL liver lipase. The results are also consistent with data showing that CGI-58 affects cellular TG catabolism and the synthesis of very low density lipoproteins in cultured hepatoma cell lines (38, 39).
In addition to its function in activating ATGL, CGI-58 was shown to operate as a lysophosphatidic acid acyltransferase (LPAAT) in vitro (25, 26). This finding correlates with previous studies showing that fibroblasts of patients affected with NLSDI exhibit a defect in the remodeling of TG to glycerophospholipids (31). Whether LPAAT activity is impaired in tissues and cells of NLSDI patients has not been directly examined. However, CGI-58 mutations causing NLSDI exhibited normal LPAAT activity in vitro (25). This finding questions a causative role for defective CGI-58-mediated LPAAT activity in NLSDI development. In our animal model for NLSDI, total LPAAT activity was unaffected in whole liver or skin lysates of CGI-58-deficient mice (data not shown). A causal relationship between LPAAT deficiency and excessive neutral lipid accumulation in CGI-58-deficient mice and humans also seems unlikely in a metabolic context. LPAAT activity is required for the formation of phosphatidic acid, which is a prerequisite for the synthesis of both TG and glycerophospholipids (40, 41). Consistent with defective TG synthesis, patients that lack specific isoforms of LPAAT activity (e.g. 1-acylglycerol-3-phosphate O-acyltransferase 2 deficiency) suffer from the absence of TG in cells and develop severe lipodystrophy (42, 43), whereas Cgi-58−/− mice and patients with NLSDI are characterized by excessive lipid deposition in multiple tissues. However, it is conceivable that this activity is specific to a certain cellular compartment (e.g. LD or lamellar bodies) and/or substrate (e.g. ω-OH-ceramide species, retinol, etc.) and therefore masked by the total cellular LPAAT activity.
The severe skin defect in Cgi-58−/− mice originates from an ATGL-independent mechanism, because mice and humans lacking ATGL activity do not develop ichthyosis (14, 15). Transplantation experiments of CGI-58-deficient skin onto nude mice proved that the defect was inherent to the skin and not the result of systemic metabolic alterations. To illuminate the function of CGI-58 in the skin, we analyzed its involvement in TG metabolism. In the dermis, the TG content was increased and TG hydrolase activity was decreased to a similar extent in Cgi-58−/− and Atgl−/− mice compared with wild-type samples, consistent with the view that dermal TG catabolism is predominantly mediated by ATGL. In contrast, TG content in the epidermis was much higher in Cgi-58−/− mice than in Atgl−/− and wild-type animals. Conversely, TG hydrolase activity was substantially lower in Cgi-58−/− epidermal lysates than in wild-type and Atgl−/− lysates. Defective epidermal lipolysis in the absence of CGI-58 led to an impaired TG turnover and FA release from cellular LD, as evident from pulse-chase experiments. These findings are consistent with the observation that NLSDI patients lacking functional CGI-58 accumulate TG-enriched LD in the epidermis of their skin (27). Considering that CGI-58 itself lacks TG hydrolase activity, we conclude that in addition to ATGL a lipase in the skin exists, which hydrolyzes epidermal TG. The results also imply that analogously to ATGL, this currently unknown enzyme requires CGI-58 for full activity. The existence of at least two separate neutral skin lipases, one specific for short chain TG and the other specific for long chain TG, was predicted earlier (44). A recent study surveyed human genes implicated in epidermal barrier function and presented a list of several potential candidates for the postulated epidermal TG lipase(s) on the basis of microarray expression profiling (45). The list included patatin protein family members, lipase-like genes, esterase/carboxyl esterases, and α/β-hydrolase domain containing protein family members. Whether any of these candidates are CGI-58-activated TG hydrolases with substrate specificity for long chain FA remains to be determined.
This study demonstrates a direct link between epidermal TG catabolism and the formation of a functional CLE. The formation of the CLE involves the covalent binding of ω-OH ceramides to the protein mantle of corneocytes (46). A multiple step remodeling pathway of the ceramide ligand precedes the lipid-protein bonding. According to the current concept, ω-OH-ceramides derive from the ω-hydroxylation of very long chain FA (presumably by a cytochrome P450-mediated process) and their subsequent amide formation with sphingol, a precursor of ceramides (36). ω-OH-ceramides are then acylated by esterification of the ω-OH group with oleic or linoleic acid. The resulting acylceramides are glycosylated by glucosylceramide synthase and bonded to the carboxyl termini of involucrin, by a process that involves several enzymes, including transglutaminase-1 and β-glucocerebrosidase (36). Our data show that in the absence of CGI-58, FA are trapped in cellular TG stores and not transferred to ω-OH-ceramides (and phospholipids). Accordingly, the epidermal concentration of acylceramides and protein-bound ceramides was extremely low or undetectable, whereas unbound ω-OH-ceramide levels were elevated. Inhibition of epidermal TG lipases by the nonspecific inhibitor orlistat also prevented acylceramide formation suggesting that the hydrolytic degradation of the epidermal TG pool is a requirement for the subsequent acylceramide synthesis.
The concept that FA for acylceramide formation have to cycle through esterification (TG synthesis) and re-hydrolysis (TG degradation by lipases) is also supported by induced mutant mice that lack the principal enzyme in epidermal TG synthesis, DGAT2 (acyl-CoA:diacylglycerolacyltransferase-2). DGAT2-deficient mice lacking epidermal TG synthesis also exhibited drastically reduced acylceramide concentrations in the skin (47). Yet phospholipid levels were not affected in both the DGAT2- and CGI-58-deficient mouse model. Interestingly, DGAT-2-deficient animals developed a skin phenotype very similar to that observed in CGI-58-deficient mice and also died soon after birth.
In summary, our study assigns an essential role to CGI-58 in TG catabolism. CGI-58 deficiency leads to deranged lipid accumulation in the liver suggesting that CGI-58-activated fat degradation plays an important role in hepatic TG homeostasis. Additionally, the crucial role of epidermal TG catabolism for acylceramide synthesis provided novel insights into the molecular mechanisms involved in ichthyosis development of NLSDI patients. The pharmacological activation of CGI-58-mediated TG catabolism in the skin and liver might provide a novel molecular target for the treatment of ichthyosiform skin disorders and hepatic steatosis, respectively.
Supplementary Material
Acknowledgments
We thank Dr. D. L. Brasaemle for kindly providing the rabbit polyclonal CGI-58 antiserum. We thank Dr. J. Wojciechowski for blastocyt injections, Mag. B. Juritsch and A. Hermann for their excellent technical assistance, and Dr. E. Zechner and Mag. C. Lanschützer for critically reading the manuscript.
This work was supported by Grant “GOLD-Genomics of Lipid-associated Disorders” (which is part of the Austrian Genome Project “GEN-AU Genome Research in Austria”) funded by the Austrian Ministry for Science and Research and by Grant SFB LIPOTOX F30-B05 and FWF Project P20602-B05 funded by the Austrian Fonds zur Förderung der Wissenschaftlichen Forschung.
The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1 and S2.
- FA
- fatty acid
- ATGL
- adipose triglyceride lipase
- CGI-58
- comparative gene identification-58
- CLE
- cornified lipid envelope
- DGAT2
- acyl-CoA:diacylglycerolacyltransferase-2
- MSMS
- tandem mass spectrometry
- LD
- lipid droplet
- LPAAT
- lysophosphatidic acid acyltransferase
- MEF
- murine embryonic fibroblasts
- NLSD
- neutral lipid storage disease
- ω-OH-ceramide
- ω-hydroxyceramide
- TG
- triacylglycerol
- BSA
- bovine serum albumin
- ES
- embryonic stem
- DMEM
- Dulbecco's modified Eagle's medium
- PBS
- phosphate-buffered saline
- NLSDI
- neutral lipid storage disease with ichthyosis
- UPLC
- ultra performance liquid chromatography.
REFERENCES
- 1.Dorfman M. L., Hershko C., Eisenberg S., Sagher F. (1974) Arch. Dermatol. 110, 261–266 [PubMed] [Google Scholar]
- 2.Chanarin I., Patel A., Slavin G., Wills E. J., Andrews T. M., Stewart G. (1975) Br. Med. J. 1, 553–555 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Igal R. A., Rhoads J. M., Coleman R. A. (1997) J. Pediatr. Gastroenterol. Nutr. 25, 541–547 [DOI] [PubMed] [Google Scholar]
- 4.Kahn B. B., Flier J. S. (2000) J. Clin. Invest. 106, 473–481 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Spiegelman B. M., Flier J. S. (2001) Cell 104, 531–543 [DOI] [PubMed] [Google Scholar]
- 6.Qatanani M., Lazar M. A. (2007) Genes Dev. 21, 1443–1455 [DOI] [PubMed] [Google Scholar]
- 7.Jenkins C. M., Mancuso D. J., Yan W., Sims H. F., Gibson B., Gross R. W. (2004) J. Biol. Chem. 279, 48968–48975 [DOI] [PubMed] [Google Scholar]
- 8.Villena J. A., Roy S., Sarkadi-Nagy E., Kim K. H., Sul H. S. (2004) J. Biol. Chem. 279, 47066–47075 [DOI] [PubMed] [Google Scholar]
- 9.Zimmermann R., Strauss J. G., Haemmerle G., Schoiswohl G., Birner-Gruenberger R., Riederer M., Lass A., Neuberger G., Eisenhaber F., Hermetter A., Zechner R. (2004) Science 306, 1383–1386 [DOI] [PubMed] [Google Scholar]
- 10.Holm C., Kirchgessner T. G., Svenson K. L., Fredrikson G., Nilsson S., Miller C. G., Shively J. E., Heinzmann C., Sparkes R. S., Mohandas T., et al. (1988) Science 241, 1503–1506 [DOI] [PubMed] [Google Scholar]
- 11.Raben D. M., Baldassare J. J. (2005) Trends Endocrinol. Metab. 16, 35–36 [DOI] [PubMed] [Google Scholar]
- 12.Osuga J., Ishibashi S., Oka T., Yagyu H., Tozawa R., Fujimoto A., Shionoiri F., Yahagi N., Kraemer F. B., Tsutsumi O., Yamada N. (2000) Proc. Natl. Acad. Sci. U.S.A. 97, 787–792 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Haemmerle G., Zimmermann R., Hayn M., Theussl C., Waeg G., Wagner E., Sattler W., Magin T. M., Wagner E. F., Zechner R. (2002) J. Biol. Chem. 277, 4806–4815 [DOI] [PubMed] [Google Scholar]
- 14.Haemmerle G., Lass A., Zimmermann R., Gorkiewicz G., Meyer C., Rozman J., Heldmaier G., Maier R., Theussl C., Eder S., Kratky D., Wagner E. F., Klingenspor M., Hoefler G., Zechner R. (2006) Science 312, 734–737 [DOI] [PubMed] [Google Scholar]
- 15.Fischer J., Lefèvre C., Morava E., Mussini J. M., Laforêt P., Negre-Salvayre A., Lathrop M., Salvayre R. (2007) Nat. Genet. 39, 28–30 [DOI] [PubMed] [Google Scholar]
- 16.Hirano K., Ikeda Y., Zaima N., Sakata Y., Matsumiya G. (2008) N. Engl. J. Med. 359, 2396–2398 [DOI] [PubMed] [Google Scholar]
- 17.Lass A., Zimmermann R., Haemmerle G., Riederer M., Schoiswohl G., Schweiger M., Kienesberger P., Strauss J. G., Gorkiewicz G., Zechner R. (2006) Cell Metab. 3, 309–319 [DOI] [PubMed] [Google Scholar]
- 18.Yamaguchi T., Omatsu N., Morimoto E., Nakashima H., Ueno K., Tanaka T., Satouchi K., Hirose F., Osumi T. (2007) J. Lipid Res. 48, 1078–1089 [DOI] [PubMed] [Google Scholar]
- 19.Lefèvre C., Jobard F., Caux F., Bouadjar B., Karaduman A., Heilig R., Lakhdar H., Wollenberg A., Verret J. L., Weissenbach J., Ozgüc M., Lathrop M., Prud'homme J. F., Fischer J. (2001) Am. J. Hum. Genet. 69, 1002–1012 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Subramanian V., Rothenberg A., Gomez C., Cohen A. W., Garcia A., Bhattacharyya S., Shapiro L., Dolios G., Wang R., Lisanti M. P., Brasaemle D. L. (2004) J. Biol. Chem. 279, 42062–42071 [DOI] [PubMed] [Google Scholar]
- 21.Yamaguchi T., Omatsu N., Matsushita S., Osumi T. (2004) J. Biol. Chem. 279, 30490–30497 [DOI] [PubMed] [Google Scholar]
- 22.Granneman J. G., Moore H. P., Mottillo E. P., Zhu Z. (2009) J. Biol. Chem. 284, 3049–3057 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Granneman J. G., Moore H. P., Granneman R. L., Greenberg A. S., Obin M. S., Zhu Z. (2007) J. Biol. Chem. 282, 5726–5735 [DOI] [PubMed] [Google Scholar]
- 24.Granneman J. G., Moore H. P., Krishnamoorthy R., Rathod M. (2009) J. Biol. Chem. 284, 34538–34544 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Ghosh A. K., Ramakrishnan G., Chandramohan C., Rajasekharan R. (2008) J. Biol. Chem. 283, 24525–24533 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Montero-Moran G., Caviglia J. M., McMahon D., Rothenberg A., Subramanian V., Xu Z., Lara-Gonzalez S., Storch J., Carman G. M., Brasaemle D. L. (2010) J. Lipid Res., in press [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Akiyama M., Sawamura D., Nomura Y., Sugawara M., Shimizu H. (2003) J. Invest. Dermatol. 121, 1029–1034 [DOI] [PubMed] [Google Scholar]
- 28.Taniguchi M., Sanbo M., Watanabe S., Naruse I., Mishina M., Yagi T. (1998) Nucleic Acids Res. 26, 679–680 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Ausubel F. M., Brent R., Kingston R. E., Moore D. D., Seidman J. G., Smith J. A., Struhl K. (eds) (2004) Current Protocols in Molecular Biology, Vol. 2, pp. 10.2A.1–10.2A.27, John Wiley & Sons, Inc., New York [Google Scholar]
- 30.Wertz P. W., Miethke M. C., Long S. A., Strauss J. S., Downing D. T. (1985) J. Invest. Dermatol. 84, 410–412 [DOI] [PubMed] [Google Scholar]
- 31.Igal R. A., Coleman R. A. (1996) J. Biol. Chem. 271, 16644–16651 [DOI] [PubMed] [Google Scholar]
- 32.McMahon A., Butovich I. A., Mata N. L., Klein M., Ritter R., 3rd, Richardson J., Birch D. G., Edwards A. O., Kedzierski W. (2007) Mol. Vis. 13, 258–272 [PMC free article] [PubMed] [Google Scholar]
- 33.Jordans G. H. (1953) Acta Med. Scand. 145, 419–423 [DOI] [PubMed] [Google Scholar]
- 34.Navarro J. M., Casatorres J., Jorcano J. L. (1995) J. Biol. Chem. 270, 21362–21367 [DOI] [PubMed] [Google Scholar]
- 35.Andreadis S. T., Hamoen K. E., Yarmush M. L., Morgan J. R. (2001) FASEB J. 15, 898–906 [DOI] [PubMed] [Google Scholar]
- 36.Uchida Y., Holleran W. M. (2008) J. Dermatol. Sci. 51, 77–87 [DOI] [PubMed] [Google Scholar]
- 37.Guerciolini R. (1997) Int. J. Obes. Relat. Metab. Disord. 21, Suppl. 3, 12–23 [PubMed] [Google Scholar]
- 38.Brown J. M., Chung S., Das A., Shelness G. S., Rudel L. L., Yu L. (2007) J. Lipid Res. 48, 2295–2305 [DOI] [PubMed] [Google Scholar]
- 39.Caviglia J. M., Sparks J. D., Toraskar N., Brinker A. M., Yin T. C., Dixon J. L., Brasaemle D. L. (2009) Biochim. Biophys. Acta 1791, 198–205 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Péterfy M., Phan J., Xu P., Reue K. (2001) Nat. Genet. 27, 121–124 [DOI] [PubMed] [Google Scholar]
- 41.Han G. S., Wu W. I., Carman G. M. (2006) J. Biol. Chem. 281, 9210–9218 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Agarwal A. K., Arioglu E., De Almeida S., Akkoc N., Taylor S. I., Bowcock A. M., Barnes R. I., Garg A. (2002) Nat. Genet. 31, 21–23 [DOI] [PubMed] [Google Scholar]
- 43.Garg A., Agarwal A. K. (2009) Biochim. Biophys. Acta 1791, 507–513 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Hilaire N., Salvayre R., Thiers J. C., Bonnafé M. J., Nègre-Salvayre A. (1995) J. Biol. Chem. 270, 27027–27034 [DOI] [PubMed] [Google Scholar]
- 45.Toulza E., Mattiuzzo N. R., Galliano M. F., Jonca N., Dossat C., Jacob D., de Daruvar A., Wincker P., Serre G., Guerrin M. (2007) Genome Biol. 8, R107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Candi E., Schmidt R., Melino G. (2005) Nat. Rev. Mol. Cell Biol. 6, 328–340 [DOI] [PubMed] [Google Scholar]
- 47.Stone S. J., Myers H. M., Watkins S. M., Brown B. E., Feingold K. R., Elias P. M., Farese R. V., Jr. (2004) J. Biol. Chem. 279, 11767–11776 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.